Insider Trading Alert - ILMN, MMS, APU, ENR And PRXL Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Feb. 10, 2014, 89 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $310.00 to $48,325,837.35.

Highlighted Stocks Traded by Insiders:

Illumina (ILMN) - FREE Research Report

Flatley Jay T who is Ceo at Illumina sold 5,000 shares at $152.23 on Feb. 10, 2014. Following this transaction, the Ceo owned 6,000 shares meaning that the stake was reduced by 45.45% with the 5,000-share transaction.

The shares most recently traded at $160.77, up $8.54, or 5.31% since the insider transaction. Historical insider transactions for Illumina go as follows:

  • 4-Week # shares sold: 12,884
  • 12-Week # shares sold: 17,884
  • 24-Week # shares sold: 49,511

The average volume for Illumina has been 1.6 million shares per day over the past 30 days. Illumina has a market cap of $19.8 billion and is part of the health care sector and drugs industry. Shares are up 41.88% year-to-date as of the close of trading on Monday.

Illumina, Inc. develops, manufactures, and markets life science tools and integrated systems for the analysis of genetic variation and biological function in North America, Europe, Latin America, the Asia-Pacific, the Middle East, and South Africa. The company has a P/E ratio of 87.2. Currently there are 7 analysts that rate Illumina a buy, no analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ILMN - FREE

TheStreet Quant Ratings rates Illumina as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in net income. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Illumina Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Roku, Nucana and Other IPOs That Should Be on Your Radar in 2017

Illumina Lights the Way for Biotechs

Illumina Lights the Way for Biotechs

Trader's Daily Notebook: Anemic Trading Would Be an Improvement